Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Delves Deeper Into Biosimilars With Tocilizumab Partnership

Signs Agreement With China’s Bio-Thera Solutions Worth Over $30m

Executive Summary

Biogen has broken new ground in its biosimilar endeavors, expanding beyond its partnership with its part-owned Samsung Bioepis company by agreeing a deal for rights to Bio-Thera Solutions’ BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.

You may also be interested in...



FDA Accepts Kabi’s Actemra Biosimilar – Will It Be First?

Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”

Celltrion Gets Ready To Push Tocilizumab Into Phase III

Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.

Roche Makes Tocilizumab Launch Prediction As Biosimilars Progress

Roche gave small insight into its expectations around biosimilar competition for its Actemra/RoActemra (tocilizumab) treatment for inflammatory diseases. Extraordinary demand for the biologic led sales to skyrocket by 143% in the third quarter and caused supply constraints for the originator.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel